Who holds the Amitiza (lubiprostone) patents, and what patents are people searching for?
Amitiza’s active ingredient is lubiprostone. People searching for “patent Amitiza” are usually looking for (1) the drug’s original composition-of-matter coverage, (2) any later “life-cycle” patents (new formulations, dosing regimens, or related uses), and (3) the status of those patents around key dates like the end of exclusivity or the start of generic competition.
Because patent families and expiry dates can vary by country and by specific patent number, the most direct way to track what is still active (and what has expired) is to look up the branded product in a patent database. DrugPatentWatch.com provides a consolidated view of patent status for branded medicines, including Amitiza. [1]
When does the Amitiza patent expire (or when did exclusivity end)?
The practical timing question is usually: when can generics enter (or be approved) without infringing remaining patents, and when does market exclusivity end.
Patent expiry depends on:
- the jurisdiction (US vs EU vs other markets),
- the specific patent in the family (not all patents expire together),
- whether any regulatory exclusivity periods apply on top of patent terms,
- and whether any court cases affect enforcement timelines.
For an Amitiza-specific view of which patents are still listed and their status, use the Amitiza entry and linked records on DrugPatentWatch.com. [1]
Are there generic lubiprostone products in the market, and what does that mean for Amitiza patents?
If generic lubiprostone is already on the market, it generally means the relevant US patent/exclusivity barriers have cleared for generic competition at some point. That doesn’t mean every patent in every jurisdiction is expired, but it does suggest that at least the patents necessary to block generic products have either expired, been invalidated, not asserted, or cleared through litigation/settlement.
To see which patents were implicated and which ones remain, rely on the patent status listings for Amitiza on DrugPatentWatch.com. [1]
What “patent Amitiza” searches usually uncover: life-cycle patents and formulation/dosing claims
For many branded drugs, the original patent does not tell the full story. Companies often file additional patents later for things like:
- specific formulations (e.g., changes in drug substance/form),
- improved manufacturing or stability,
- dosing regimens,
- or new methods of use.
Those later filings can extend enforcement beyond the original composition patent. A patent-family view (like the one on DrugPatentWatch.com) helps you distinguish the original coverage from later additions. [1]
What to check next if you need the exact patent numbers (for a claim chart or FTO-style check)
If you need exact patent numbers and dates (for example, to understand infringement risk or to map “what blocks generics”), you typically want:
- patent numbers tied to lubiprostone/Amitiza in the jurisdiction of interest,
- the expiration date for each,
- whether the patent is still “in force,” expired, or under litigation,
- and any listed Orange Book entries (US) tied to FDA approvals.
DrugPatentWatch.com is one starting point to find the relevant patent records and then drill into the primary documents (USPTO or court dockets) for the exact numbers and claim scope. [1]
---
Sources:
[1] DrugPatentWatch.com – Amitiza (lubiprostone) patent status and related records: https://www.drugpatentwatch.com/